The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases

Andre Gorgen, Hala Muaddi, Wei Zhang, Ian McGilvray, Steven Gallinger, Gonzalo Sapisochin, Andre Gorgen, Hala Muaddi, Wei Zhang, Ian McGilvray, Steven Gallinger, Gonzalo Sapisochin

Abstract

Colorectal cancer (CRC) is the third most incident cancer worldwide. Most of CRC patients will develop distant metastases, mainly to the liver, and liver resection is the only potential chance for cure. On the other hand, only a small proportion of patients with hepatic CRC metastasis are candidates for upfront liver resection. Liver transplantation (LT) is an attractive option for patients with nonresectable CRC liver metastases (NRCLM) without extrahepatic involvement. Initial experiences with LT for NRCLM achieved very poor outcomes, with a 5-year overall survival (OS) lower than 20%. However, these initial studies did not have a standardized patient selection or neoadjuvant or adjuvant therapies. With recent advances in the surgical and medical oncology fields, the landscape has changed. Recent studies from Norway have shown an encouraging 5-year OS of 50% when transplanting patients with NRCLM. Nevertheless, the main concern when expanding the indications for LT is organ shortage. To manage this organ shortage, strategies utilizing live donor liver transplantation are gaining favor. A few ongoing trials are assessing the impact of LT in NRCLM patient survival. Therefore, the aim of this paper is to review the current status of LT for NRCLM.

References

    1. Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2014 doi: 10.1002/ijc.29210.
    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2016. Toronto, Canada: Canadian Cancer Society;
    1. Center M. M., Jemal A., Smith R. A., Ward E. Worldwide variations in colorectal cancer. CA: A Cancer Journal for Clinicians. 2009;59(6):366–378. doi: 10.3322/caac.20038.
    1. Siegel R. L., Miller K. D., Jemal A. Colorectal cancer mortality rates in adults aged 20 to 54 years in the united states, 1970–2014. Journal of the American Medical Association. 2017;318(6):p. 572. doi: 10.1001/jama.2017.7630.
    1. van der Geest L. G. M., Lam-Boer J., Koopman M., Verhoef C., Elferink M. A. G., de Wilt J. H. W. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clinical & Experimental Metastasis. 2015;32(5):457–465. doi: 10.1007/s10585-015-9719-0.
    1. van Gestel Y. R. B. M., de Hingh I. H. J. T., van Herk-Sukel M. P. P., et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiology. 2014;38(4):448–454. doi: 10.1016/j.canep.2014.04.004.
    1. Van Cutsem E., Cervantes A., Adam R., Sobrero A., Van Krieken J. H., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 2016;27(8):1386–1422.
    1. Siegel R. L., Miller K. D., Fedewa S. A., et al. Colorectal cancer statistics. CA: A Cancer Journal for Clinicians. 2017;67(3):177–193. doi: 10.3322/caac.21395.
    1. Benson A. B., Bekaii-Saab T., Chan E., Chen Y. J., et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2013;11(2):141–152. Quiz 152.
    1. Bartlett D. L., Chu E. Can metastatic colorectal cancer be cured? Oncology. 2012;26(3):266–275.
    1. House M. G., Ito H., Gönen M., et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. Journal of the American College of Surgeons. 2010;210(5):744–752. doi: 10.1016/j.jamcollsurg.2009.12.040.
    1. Wei A. C., Greig P. D., Grant D., Taylor B., Langer B., Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Annals of Surgical Oncology. 2006;13(5):668–676. doi: 10.1245/ASO.2006.05.039.
    1. Leal J. N., Bressan A. K., Vachharajani N., et al. Time-to-surgery and survival outcomes in resectable colorectal liver metastases: a multi-institutional evaluation. Journal of the American College of Surgeons. 2016;222(5):766–779. doi: 10.1016/j.jamcollsurg.2016.01.046.
    1. Viganò L., Capussotti L., Lapointe R., et al. Early recurrence after liver resection for colorectal metastases: Risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Annals of Surgical Oncology. 2014;21(4):1276–1286. doi: 10.1245/s10434-013-3421-8.
    1. Bredt L. C., Rachid A. F. Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World Journal of Surgical Oncology. 2014;12, article 391 doi: 10.1186/1477-7819-12-391.
    1. Devaud N., Kanji Z. S., Dhani N., et al. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases. HPB. 2014;16(5):475–480. doi: 10.1111/hpb.12159.
    1. Pawlik T. M., Scoggins C. R., Zorzi D., et al. Effect of Surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Annals of Surgery. 2005;241(5):715–724. doi: 10.1097/01.sla.0000160703.75808.7d.
    1. Wurster E. F., Tenckhoff S., Probst P., et al. A systematic review and meta-analysis of the utility of repeated versus single hepatic resection for colorectal cancer liver metastases. HPB. 2017;19(6):491–497. doi: 10.1016/j.hpb.2017.02.440.
    1. Sanoff H. K., Sargent D. J., Campbell M. E., et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. Journal of Clinical Oncology. 2008;26(35):5721–5727. doi: 10.1200/JCO.2008.17.7147.
    1. Manfredi S., Lepage C., Hatem C., Coatmeur O., Faivre J., Bouvier A.-M. Epidemiology and management of liver metastases from colorectal cancer. Annals of Surgery. 2006;244(2):254–259. doi: 10.1097/.
    1. Pulitano C., Crawford M., Joseph D., Aldrighetti L., Sandroussi C. Preoperative assessment of postoperative liver function: the importance of residual liver volume. Journal of Surgical Oncology. 2014;110(4):445–450. doi: 10.1002/jso.23671.
    1. Kwong A. J., Lai J. C., Dodge J. L., Roberts J. P. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score. Liver Transplantation. 2015;21(11):1403–1409. doi: 10.1002/lt.24307.
    1. Umgelter A., Hapfelmeier A., Kopp W., van Rosmalen M., Rogiers X., Guba M. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions. Liver Transplantation. 2017;23(10):1256–1265. doi: 10.1002/lt.24805.
    1. Chapman W. C. Liver transplantation for unresectable metastases to the liver: a new era in transplantation or a time for caution? Annals of Surgery. 2013;257(5):816–817. doi: 10.1097/SLA.0b013e3182908c8d.
    1. Sapisochin G., Bruix J. Liver transplantation for hepatocellular carcinoma: Outcomes and novel surgical approaches. Nature Reviews Gastroenterology & Hepatology. 2017;14(4):203–217. doi: 10.1038/nrgastro.2016.193.
    1. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. The New England Journal of Medicine. 1996;334(11):693–699. doi: 10.1056/NEJM199603143341104.
    1. Kim W. R., Lake J. R., Smith J. M., et al. OPTN/SRTR 2015 Annual Data Report: Liver. American Journal of Transplantation. 2017;17(S1):174–251. doi: 10.1111/ajt.14126.
    1. Zarrinpar A., Busuttil R. W. Liver transplantation: past, present and future. Nature Reviews Gastroenterology & Hepatology. 2013;10(7):434–440. doi: 10.1038/nrgastro.2013.88.
    1. De Vreede I., Steers J. L., Burch P. A., et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transplantation. 2000;6(3):309–316. doi: 10.1053/lv.2000.6143.
    1. Austin M. T., Leys C. M., Feurer I. D., et al. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. Journal of Pediatric Surgery. 2006;41(1):182–186. doi: 10.1016/j.jpedsurg.2005.10.091.
    1. Pavel M., Baudin E., Couvelard A., et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–176. doi: 10.1159/000335597.
    1. Hibi T., Itano O., Shinoda M., Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of “Transplant Oncology” has begun. Surgery Today. 2017;47(4):403–415. doi: 10.1007/s00595-016-1337-1.
    1. Mühlbacher F., Huk I., Steininger R., Gnant M., Götzinger P., et al. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplantation Proceedings. 1991;23(1, part 2):1567–1568.
    1. Mühlbacher F., Piza F. Orthotopic liver transplantation for secondary malignancies of the liver. Transplantation Proceedings. 1987;19(1):2396–2398.
    1. Moris D., Tsilimigras D. I., Chakedis J., et al. Liver transplantation for unresectable colorectal liver metastases: A systematic review. Journal of Surgical Oncology. 2017;116(3):288–297. doi: 10.1002/jso.24671.
    1. Kappel S., Kandioler D., Steininger R., et al. Genetic detection of lymph node micrometastases: a selection criterion for liver transplantation in patients with liver metastases after colorectal cancer. Transplantation. 2006;81(1):64–70. doi: 10.1097/01.tp.0000189711.98971.9c.
    1. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery. 1991;110(4):726–734. Discussion 734-735.
    1. Foss A., Adam R., Dueland S. Liver transplantation for colorectal liver metastases: Revisiting the concept. Transplant International. 2010;23(7):679–685. doi: 10.1111/j.1432-2277.2010.01097.x.
    1. Hoti E., Adam R. Liver transplantation for primary and metastatic liver cancers. Transplant International. 2008;21(12):1107–1117. doi: 10.1111/j.1432-2277.2008.00735.x.
    1. Andersen M. H., Dueland S., Hagness M., et al. Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma. Scandinavian Journal of Caring Sciences. 2012;26(4):713–719. doi: 10.1111/j.1471-6712.2012.00984.x.
    1. Hagness M., Foss A., Line P.-D., Scholz T., et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Annals of Surgery. 2013;257(5):800–806. doi: 10.1097/SLA.0b013e3182823957.
    1. Toso C., Pinto Marques H., Andres A., et al. Liver transplantation for colorectal liver metastasis: Survival without recurrence can be achieved. Liver Transplantation. 2017;23(8):1073–1076. doi: 10.1002/lt.24791.
    1. Lucas A. S., O'Neil B. H., Goldberg R. M. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clinical Colorectal Cancer. 2011;10(4):238–244. doi: 10.1016/j.clcc.2011.06.012.
    1. Hagness M., Foss A., Egge T. S., Dueland S. Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer. Annals of Surgical Oncology. 2014;21(4):1323–1329. doi: 10.1245/s10434-013-3449-9.
    1. Bellier J., De Wolf J., Hebbar M., et al. Repeated resections of hepatic and pulmonary metastases from colorectal cancer provide long-term survival. World Journal of Surgery. 2017:1–9. doi: 10.1007/s00268-017-4265-3.
    1. D'Angelica M., Kornprat P., Gonen M., et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Annals of Surgical Oncology. 2011;18(4):1096–1103. doi: 10.1245/s10434-010-1409-1.
    1. Dueland S., Guren T. K., Hagness M., Glimelius B., Line P.-D., et al. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Annals of Surgery. 2015;261(5):956–960. doi: 10.1097/SLA.0000000000000786.
    1. Tveit K. M., Guren T., Glimelius B., et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. Journal of Clinical Oncology. 2012;30(15):1755–1762. doi: 10.1200/JCO.2011.38.0915.
    1. Chua T. C., Liauw W., Chu F., Morris D. L. Viewing metastatic colorectal cancer as a curable chronic disease. American Journal of Clinical Oncology. 2012;35(1):77–80. doi: 10.1097/COC.0b013e3181fe4444.
    1. Grossmann I., Doornbos P. M., Klaase J. M., De Bock G. H., Wiggers T. Changing patterns of recurrent disease in colorectal cancer. European Journal of Surgical Oncology. 2014;40(2):234–239. doi: 10.1016/j.ejso.2013.10.028.
    1. Adam R., Wicherts D. A., De Haas R., et al. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? Journal of Clinical Oncology. 2009;27(11):1829–1835. doi: 10.1200/JCO.2008.19.9273.
    1. Leung U., Gönen M., Allen P. J., et al. Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection. Annals of Surgery. 2017;265(1):158–165. doi: 10.1097/SLA.0000000000001624.
    1. Abdalla E. K., Bauer T. W., Chun Y. S., D’Angelica M., Kooby D. A., Jarnagin W. R. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB. 2013;15(2):119–130. doi: 10.1111/j.1477-2574.2012.00597.x.
    1. Zaydfudim V. M., McMurry T. L., Harrigan A. M., et al. Improving treatment and survival: a population-based study of current outcomes after a hepatic resection in patients with metastatic colorectal cancer. HPB. 2015;17(11):1019–1024. doi: 10.1111/hpb.12488.
    1. Dutkowski P., Clavien P.-A. Solutions to shortage of liver grafts for transplantation. British Journal of Surgery. 2014;101(7):739–741. doi: 10.1002/bjs.9540.
    1. Aguiar Martins P. N., Movahedi B., Bozorgzadeh A. Liver transplantation for unresectable colorectal cancer liver metastases: a paradigm change? Annals of Surgery. 2015;262(1):p. e12. doi: 10.1097/SLA.0000000000000483.
    1. Merion R. M., Pelletier S. J., Goodrich N., Englesbe M. J., Delmonico F. L. Donation after cardiac death as a strategy to increase deceased donor liver availability. Annals of Surgery. 2006;244(4):555–560. doi: 10.1097/01.sla.0000239006.33633.39.
    1. Emre S., Schwartz M. E., Altaca G., et al. Safe use of hepatic allografts from donors older than 70 years. Transplantation. 1996;62(1):62–65. doi: 10.1097/00007890-199607150-00013.
    1. McCormack L., Dutkowski P., El-Badry A. M., Clavien P.-A. Liver transplantation using fatty livers: always feasible? Journal of Hepatology. 2011;54(5):1055–1062. doi: 10.1016/j.jhep.2010.11.004.
    1. Monbaliu D., Pirenne J., Talbot D. Liver transplantation using donation after cardiac death donors. Journal of Hepatology. 2012;56(2):474–485. doi: 10.1016/j.jhep.2011.07.004.
    1. Vagefi P. A., Parekh J., Ascher N. L., Roberts J. P., Freise C. E. Outcomes with split liver transplantation in 106 recipients: The University of California, San Francisco, experience from 1993 to 2010. JAMA Surgery. 2011;146(9):1052–1059. doi: 10.1001/archsurg.2011.218.
    1. Citerio G., Cypel M., Dobb G. J., et al. Organ donation in adults: a critical care perspective. Intensive Care Medicine. 2016;42(3):305–315. doi: 10.1007/s00134-015-4191-5.
    1. Miller C. M., Durand F., Heimbach J. K., et al. The International Liver Transplant Society Guideline on Living Liver Donation. Transplantation. 2016;100(6):1238–1243. doi: 10.1097/TP.0000000000001247.
    1. Sapisochin G., Goldaracena N., Laurence J. M., Levy G. A., Grant D. R., Cattral M. S. Right lobe living-donor hepatectomy-the Toronto approach, tips and tricks. Hepatobiliary Surgery and Nutrition. 2016;5(2):118–126.
    1. Sapisochin G. University Health Network, Toronto. Assessment of a protocol using a combination of neo-adjuvant chemotherapy plus living donor liver transplantation for non-resectable liver metastases from colorectal cancer. (2016, 2017 Oct 10), .
    1. Rössler F., Sapisochin G., Song G., et al. Defining benchmarks for major liver surgery: a multicenter analysis of 5202 living liver donors. Annals of Surgery. 2016;264(3):492–500. doi: 10.1097/SLA.0000000000001849.
    1. Kadry Z., Mc Cormack L., Clavien P.-A. Should living donor liver transplantation be part of every liver transplant program? Journal of Hepatology. 2005;43(1):32–37. doi: 10.1016/j.jhep.2005.05.006.
    1. Dueland S. Oslo University Hospital, Oslo. A randomized controlled clinical trial to evaluate the benefit and efficacy of liver transplantation as treatment for selected patients with liver metastases from colorectal carcinoma. (2011, 2017 Oct 10), .
    1. Dueland S. Oslo University Hospital, Oslo. A Phase I/II clinical trial to evaluate the benefit and efficacy of liver resection and partial liver segment 2/3 transplantation with delayed total hepatectomy as treatment for selected patients with liver metastases from colorectal carcinoma. (2014, 2017 Oct 10), .
    1. Line P.-D., Hagness M., Berstad A. E., Foss A., Dueland S. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept. Annals of Surgery. 2015;262(1):e5–e9. doi: 10.1097/SLA.0000000000001165.
    1. Adam R. Paul Brousse Hospital, Villejuif. Curative potential of liver transplantation in patients with definitively unresectable colorectal liver metastases (CLM) treated by chemotherapy: a prospective multicentric randomized trial. (2015, 2017 Oct 10), .
    1. Knight S. R., Morris P. J., Schneeberger S., Pengel L. H. M. Trial design and endpoints in clinical transplant research. Transplant International. 2016;29(8):870–879. doi: 10.1111/tri.12743.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe